产品描述 概述Murine IFN-lambda 2 (IL-28A), IFN-lambda 3 (IL-28B) are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11 - 13% amino acid sequence identity) and type I IFN family (15 - 19% a.a. sequence identity). These cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 R beta) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Murine IL-28B shares 63%, 63%, and 52% a.a. identity with human IL-28A, IL-28B, and IL-29, respectively. 使用说明This material is offered by Novin Biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. 技术规格| AA Sequence | DPVPRATRLP VEAKDCHIAQ FKSLSPKELQ AFKKAKGAIE KRLLEKDMRC SSHLISRAWD LKQLQVQERP KALQAEVALT LKVWENINDS ALTTILGQPL HTLSHIHSQL QTCTQLQATA EPKPPSRRLS RWLHRLQEAQ SKETPGCLED SVTSNLFQLL LRDLKCVASG DQCV | | Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. | | Endotoxin | Less than 1 EU/μg of rMuIFN-λ3/IL-28B as determined by LAL method. | | Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. | | Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 30 ng/ml, corresponding to a specific activity of > 3.3 × 104 IU/mg. | | Source | Escherichia coli. | | Purity | > 98 % by SDS-PAGE and HPLC analyses. | | Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
|
